EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Prognostic value of 1-year [18F]FDG-PET–CT-defined complete metabolic response in metastatic clear-cell renal cell carcinoma: a multicentre, observational cohort study in China

Chang Lei, Yujia Cai, Yanping Tang, Shaohao Chen, Hengshan Ji, Jincheng Zhu, Hong Gao, Łukasz Zapała, Xiao Li, Hongzhou Cai, Shiming Zang, Yuzheng Ge und 8 weitere

The Lancet Medical Imaging & Theranostics · 2026

DOI: 10.1016/j.lanmit.2026.100005 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Chang Lei und 19 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Research Program of Jiangsu Province, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In metastatic clear-cell renal cell carcinoma (mccRCC), residual lesions on CT after immune checkpoint blockade (ICB)-based therapy often remain anatomically visible despite uncertain biological viability. In this study, we evaluated whether 1-year [ 18 F]fluorodeoxyglucose ([ 18 F]FDG)-PET–CT-defined complete metabolic response (CMR), assessed at a prespecified landmark among patients who remained progression free throughout the first treatment year, provides complementary prognostic information beyond CT-based response assessment.

Methods

In this multicentre, observational cohort study with prospective follow-up at eight tertiary hospitals in China, we included patients (≥18 years) with histologically confirmed mccRCC who received first-line ICB-based combination therapy, remained progression free per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 throughout the first treatment year, and completed paired baseline and 1-year [ 18 F]FDG-PET–CT scans. Patients initiated first-line therapy between Jan 1, 2021, and Jan 31, 2024, and the analytical data cutoff was April 30, 2025. Response at the 1-year landmark was assessed using RECIST 1.1 and modified European Organisation for Research and Treatment of Cancer criteria. The primary endpoints were progression-free survival and overall survival from the 1-year landmark. All patients meeting prespecified eligibility criteria constituted the full analytical set for the primary endpoints.

Findings

Of 867 patients screened after baseline [ 18 F]FDG-PET–CT, 339 met the prespecified landmark eligibility criteria and formed the final 1-year landmark cohort. 268 (79%) of 339 patients were male and 71 (21%) were female. At the 1-year landmark, conventional CT identified complete response in 28 (8%) of 339 patients and [ 18 F] FDG-PET–CT identified CMR in 78 (23%) patients. Median follow-up from the 1-year landmark was 17·0 months (IQR 5·7–24·7). Median progression-free survival was 22·6 months (95% CI 20·0–not reached) in the CMR group versus 10·9 months (8·9–13·5) in the non-CMR group (hazard ratio [HR] 0·32, 95% CI 0·22–0·48; p

Förderung

  • Basic Research Program of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Lei, C., Cai, Y., Tang, Y., Chen, S., Ji, H., Zhu, J., Gao, H., Zapała, Ł., Li, X., Cai, H., Zang, S., Ge, Y., Chen, J., Li, Q., Sun, X., Zhao, H., Wang, F., Wu, J., Shao, P., & Qu, L. (2026). Prognostic value of 1-year [18F]FDG-PET–CT-defined complete metabolic response in metastatic clear-cell renal cell carcinoma: a multicentre, observational cohort study in China. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100005

Vancouver

Lei C, Cai Y, Tang Y, Chen S, Ji H, Zhu J, et al. Prognostic value of 1-year [18F]FDG-PET–CT-defined complete metabolic response in metastatic clear-cell renal cell carcinoma: a multicentre, observational cohort study in China. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100005

BibTeX
@article{Lei2026,
  author = {Lei, Chang and Cai, Yujia and Tang, Yanping and Chen, Shaohao and Ji, Hengshan and Zhu, Jincheng and Gao, Hong and Zapała, Łukasz and Li, Xiao and Cai, Hongzhou and Zang, Shiming and Ge, Yuzheng and Chen, Jian and Li, Quanying and Sun, Xiubin and Zhao, Hongwei and Wang, Feng and Wu, Jiang and Shao, Pengfei and Qu, Le},
  title = {Prognostic value of 1-year [18F]FDG-PET–CT-defined complete metabolic response in metastatic clear-cell renal cell carcinoma: a multicentre, observational cohort study in China},
  journal = {The Lancet Medical Imaging & Theranostics},
  year = {2026},
  doi = {10.1016/j.lanmit.2026.100005}
}
Kostenlos starten →